I-Mab and Korea's ABL Bio Start Phase I Trial of Partnered Bispecific

Shanghai 's I-Mab has dosed the first patient in a US Phase I trial of a novel bispecific antibody. I-Mab, which is developing TJ-L14B/ABL503 together with ABL Biotech of Korea , contributed its PD-L1 to the combination therapy. ABL, a bispecific company, contributed 4-1BB, a conditional T cell activator that becomes active only in the presence of PD-L1 expressing tumor cells. The two companies will enroll patients with locally advanced or metastatic solid tumors. More details.... Stock Symbols: (NSDQ: IMAB) (Kosdaq: 298380) Share this with colleagues: // //